NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全身性硬化症(硬皮症):至2030年的流行病學預測

Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030

出版商 GlobalData 商品編碼 1008863
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
全身性硬化症(硬皮症):至2030年的流行病學預測 Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030
出版日期: 2021年05月31日內容資訊: 英文 42 Pages
簡介

本報告概述了SSc在七個主要市場(7MM:美國、法國、德國、意大利、西班牙、英國和日本)的風險因素、合併症以及全球和歷史流行病學趨勢。該報告包括對診斷出的SSc流行病例的10年流行病學預測。主要7個國家市場上全身性硬化症(硬皮症)的確診病例2020年為17萬921例,預測期間預計以0.97%的AGR成長,2030年增加到18萬7,518案例。主要7個國家市場上,全身性硬化症(硬皮症)和確診的患病人數女性比男性多,老年人大量發病。

本報告提供7個主要市場(美國,法國,德國,義大利,西班牙,英國,日本的)全身性硬化症(硬皮症)的相關調查,提供疾病概要,流行病學預測,市場疾病趨勢及分析,COVID-19的影響等資訊。

目錄

目錄

第1章 全身性硬化症(硬皮症):摘要整理

  • 催化劑
  • 相關報告
  • 今後的報告

第2章 流行病學

  • 病的背景
  • 危險因素和合併症
  • 世界及歷史的趨勢
  • 7個國家的主要市場預測調查手法
    • 資訊來源
    • 預測的前提條件與方法
    • 預測的前提條件與方法:全身性硬化症(硬皮症)-7個國家的主要市場診斷的一般案例
    • 預測的前提條件與方法:各亞型確診的全身性硬化症(硬皮症)的一般病例
    • 數位血管障礙的全身性硬化症(硬皮症)的一般病例的診斷
    • 其他內臟受累及合併症的確診的一般病例
  • 全身性硬化症(硬皮症)的流行病學預測(2020-2030)
    • 全身性硬化症(硬皮症)的確診的一般病例
    • 各年齡:全身性硬化症(硬皮症)的確診的一般病例
    • 性別:全身性硬化症(硬皮症)的確診的一般病例
    • 各子類型:全身性硬化症(硬皮症)的確診的一般病例
    • 各末稍血管疾病:全身性硬化症(硬皮症)的確診的一般病例
    • 各其他的內臟的參與:全身性硬化症(硬皮症)的確診的一般病例
    • 並存的惡性腫瘤伴隨的全身性硬化症(硬皮症)的確診的一般病例
  • 討論
    • 流行病學性預測的洞察
    • COVID-19的影響
    • 分析的限制
    • 分析的優勢

第3章 附錄

  • 參考文件
  • 關於作者
    • 流行病學者
    • 檢閱者
    • 全球治療分析及流行病學董事
    • 全球醫療保健事業及策略的負責人兼EVP
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER273-21

Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue. SSc is characterized by the buildup of scar tissue (fibrosis) and vascular obliteration in the skin and organs, particularly the lungs, heart, and digestive tract (Orphanet, 2010). The signs and symptoms of SSc usually begin with episodes of Raynaud's phenomenon (RP). The other signs usually appear a few months later in the dcSSc subset and some years later in the lcSSc subset. In lcSSc, skin involvement is limited to the hands, face, feet and forearms while in the dcSSc it rapidly becomes generalized. The most commonly affected organs are the esophagus, heart, lungs, and kidneys (Genetic and Rare Diseases Information Center, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc. The diagnosed prevalent cases of SSc are segmented by age (18 years and older), sex, subtype (lcSSc and dcSSc), digital vasculopathy (RP and fingertip or DUs), and other internal organ involvement (ILD, PAH, kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The following data describes epidemiology of SSc. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of SSc from 170,921 cases in 2020 to 187,518 cases in 2030, at an AGR of 0.97% over the forecast period. Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the diagnosed prevalent cases for the 7MM.

Scope

  • The Systemic Sclerosis (SSc) Epidemiology Report provides an overview of the risk factors and global trends of SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of SSc are further segmented by subtype (lcSSc and dcSSc), digital vasculopathy (Raynaud's phenomenon [RP] and fingertip or digital ulcers [DU]), and other internal organ involvement (interstitial lung disease [ILD], pulmonary arterial hypertension [PAH], kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The model associated with this report additionally provides diagnosed incident cases and total prevalent cases of SSc segmented by age (≥18 years) and sex.
  • The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Systemic Sclerosis Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SSc market.
  • Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
  • Understand magnitude of SSc population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

Table of Contents

1 Systemic Sclerosis: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc - 7MM
    • 2.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype
    • 2.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
    • 2.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities
  • 2.5 Epidemiological Forecast for Systemic Sclerosis (Scleroderma) (2020-2030)
    • 2.5.1 Diagnosed Prevalent Cases of SSc
    • 2.5.2 Age-Specific Diagnosed Prevalent Cases of SSc
    • 2.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc
    • 2.5.4 Diagnosed Prevalent Cases of SSc by Subtype
    • 2.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
    • 2.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement
    • 2.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 3.3 Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for SSc
  • Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 7MM, Diagnosed Prevalence of SSc, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SSc
  • Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Subtype
  • Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - ILD, PAH, and Kidney Disease
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - Cardiac Involvement, Gastrointestinal Involvement, Musculoskeletal Involvement, and Neuromuscular Involvement; and Comorbidity - Malignancy
  • Figure 8: 7MM, Diagnosed Prevalent Cases of SSc, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 9: 7MM, Diagnosed Prevalent Cases of SSc by Age, N, Both Sexes, 2020
  • Figure 10: 7MM, Diagnosed Prevalent Cases of SSc by Sex, N, Ages ≥18 Years, 2020
  • Figure 11: 7MM, Diagnosed Prevalent Cases of SSc by Subtype, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 12: 7MM, Diagnosed Prevalent Cases of SSc by Digital Vasculopathy, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 13: 7MM, Diagnosed Prevalent Cases of SSc with Comorbid Malignancy, N, Both Sexes, Ages ≥18 Years, 2020